On Thursday, Pfizer announced plans to advance its weight-loss pill after "encouraging" results from an early-stage study.  The pharmaceutical giant is trying to tap into the highly lucrative market for obesity drugs currently dominated by the likes of Eli Lilly and Novo Nordisk. HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY Pfizer said it has a "robust pipeline" of three clinical and several other pre-clinical candidates but that danuglipron, a once-a-day oral treatment, was "th ...